David Ryall Brown
Fondateur chez Healx Ltd.
Profil
David Ryall Brown is the founder of Crescendo Biologics Ltd.
(founded in 2007) and Healx Ltd.
(founded in 2014, where he holds the title of Chairman).
Currently, he is the Non-Executive Chairman at Profactor Pharma Ltd.
(where he is still employed).
Previously, he held the position of Chairman at Babraham Bioscience Technologies Ltd.
and Indigix Ltd., and the position of Principal at GlaxoWellcome.
Postes actifs de David Ryall Brown
| Sociétés | Poste | Début |
|---|---|---|
Healx Ltd.
 Healx Ltd. BiotechnologyHealth Technology Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom. | Fondateur | 01/01/2014 |
Profactor Pharma Ltd.
 Profactor Pharma Ltd. Pharmaceuticals: MajorHealth Technology ProFactor Pharma Ltd. develops and supplies recombinant blood factors for the treatment of haemophilia. The firm commercialise and supply recombinant blood factors for the treatment of haemophilia to a undersupplied world market, starting with recombinant human Factor VIII (rhFVIII). The company was founded by Richard John Cruse, Ian Garner, Bruce Vernon, Hugh Ilyine and John H. McVey in 2009 and is headquartered in Midlothian, the United Kingdom. | Président | - |
Anciens postes connus de David Ryall Brown
| Sociétés | Poste | Fin |
|---|---|---|
Babraham Bioscience Technologies Ltd.
 Babraham Bioscience Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Babraham Bioscience Technologies Ltd. provides business research and consulting services. It also offers financial and administrative services to start-up biotech companies. The company was founded in 1996 and is located in Cambridge, UK | Président | 01/08/2013 |
Indigix Ltd.
 Indigix Ltd. BiotechnologyHealth Technology Indigix Ltd. develops a novel platform technology that engineers synthetic molecules to modify immunological responses for diseases. Its applications include, treatment of diarrhoeal diseases, inflammatory bowel disease, and wound healing. The firm also provides pre-clinical testing services. The company was founded on June 11, 2010 and is headquartered in Solihull, the United Kingdom. | Président | - |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Fondateur | - |
| GlaxoWellcome /Pharmocology Unit/ | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Babraham Bioscience Technologies Ltd.
Babraham Bioscience Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Babraham Bioscience Technologies Ltd. provides business research and consulting services. It also offers financial and administrative services to start-up biotech companies. The company was founded in 1996 and is located in Cambridge, UK | Commercial Services |
| GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Indigix Ltd.
Indigix Ltd. BiotechnologyHealth Technology Indigix Ltd. develops a novel platform technology that engineers synthetic molecules to modify immunological responses for diseases. Its applications include, treatment of diarrhoeal diseases, inflammatory bowel disease, and wound healing. The firm also provides pre-clinical testing services. The company was founded on June 11, 2010 and is headquartered in Solihull, the United Kingdom. | Health Technology |
Healx Ltd.
Healx Ltd. BiotechnologyHealth Technology Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Profactor Pharma Ltd.
Profactor Pharma Ltd. Pharmaceuticals: MajorHealth Technology ProFactor Pharma Ltd. develops and supplies recombinant blood factors for the treatment of haemophilia. The firm commercialise and supply recombinant blood factors for the treatment of haemophilia to a undersupplied world market, starting with recombinant human Factor VIII (rhFVIII). The company was founded by Richard John Cruse, Ian Garner, Bruce Vernon, Hugh Ilyine and John H. McVey in 2009 and is headquartered in Midlothian, the United Kingdom. | Health Technology |